TY - JOUR T1 - Cyr61 Expression Pattern and Association with Clinicopathological Factors in Patients with Cervical Cancer JF - Anticancer Research JO - Anticancer Res SP - 2451 LP - 2456 VL - 37 IS - 5 AU - SEBASTIAN MAYER AU - BORIS GABRIEL AU - THALIA ERBES AU - SYLVIA TIMME-BRONSERT AU - MARKUS JÄGER AU - GERTA RÜCKER AU - FRANCISKA KUF AU - JIRI BOUDA AU - ALENA BARTAKOVA AU - AXEL ZUR HAUSEN AU - ELMAR STICKELER AU - GERALD GITSCH AU - MARC HIRSCHFELD Y1 - 2017/05/01 UR - http://ar.iiarjournals.org/content/37/5/2451.abstract N2 - Background/Aim: The pro-angiogenic Cyr61 protein has been associated with tumorigenesis and cancer progression in different gynecological carcinomas. In this study, we evaluated the potential impact and clinical relevance of Cyr61 expression in patients with primary non-metastatic cervical cancer (CC). Patients and Methods: Cyr61 expression was assessed in tissue specimen of 48 patients with primary CC by immunohistochemical analysis. Expression levels were scored and correlated to clinico-pathological factors and outcome data. Results: High Cyr61 expression levels were present in 54.2% of CC tissues. Associations with histological grade (p=0.030), depth of tumor invasion (p=0.007) and GOG score (p=0.027) were observed. Patients who overexpressed Cyr61 displayed an increased death rate (30.8% vs. 18.2%) and a decreased 5-year-survival (76.9% vs. 86.4%). Conclusion: Our data indicate a potential functional impact of Cyr61 in development and the progression of CC. The definite tumor-relevant function (suppressive/promoting) of Cyr61 in CC and the prognostic relevance of Cyr61 overexpression has to be evaluated in larger cohorts. ER -